Intravenous Thrombolysis Guided by Perfusion CT with Alteplase in >4.5 Hours from Stroke Onset.


Journal

Cerebrovascular diseases (Basel, Switzerland)
ISSN: 1421-9786
Titre abrégé: Cerebrovasc Dis
Pays: Switzerland
ID NLM: 9100851

Informations de publication

Date de publication:
2020
Historique:
received: 11 04 2020
accepted: 27 05 2020
pubmed: 3 7 2020
medline: 1 12 2020
entrez: 3 7 2020
Statut: ppublish

Résumé

The benefit of intravenous thrombolysis (IVT) in wake-up stroke (WUS), stroke of unknown time of onset (SUKO), or when time exceeds 4.5 h from last-seen-normal (LSN) guided by CT perfusion (CTP) or MRI has been recently suggested. However, there is limited information of IVT in those patients in real-world studies. Our aim was to evaluate safety and efficacy of IVT selected by CTP in patients with WUS, SUKO, or stroke of time onset beyond 4.5 h. We studied a prospective cohort of patients who underwent IVT from January 2010 to December 2017. Two groups were defined: standard of care group (SC) included patients with time onset <4.5 h and CTP group included patients with WUS, SUKO, or onset beyond >4.5 h from LSN with penumbra area in CTP. We evaluated baseline characteristics, functional outcomes according to modified Rankin Scale (mRS) at discharge and at 90 days, and intracranial hemorrhages rates. 657 patients were studied: 604 (92%) were treated in the SC group and 53 (8%) in the CTP group. The mean NIHSS score was 9.8 in the CTP group versus 13 in the SC group (p = 0.001). Seventeen patients in the CTP group (32.1%) received bridging therapy with mechanical thrombectomy (MT). Last time seen well-to-needle time was 538 versus 155 min (p < 0.001). The incidence of symptomatic intracranial hemorrhage was equal in both groups (3.8 vs. 3.8%, p = 1). Good functional outcome (mRS < 2) was achieved in both groups (72 vs. 60.4%, p = 0.107). IVT in patients with WUS, SUKO, or stroke beyond >4.5 h from LSN, with salvageable brain tissue on CTP, seems to be safe and has similar functional outcomes at 90 days to the standard therapeutic window, even when combined with MT.

Identifiants

pubmed: 32615572
pii: 000509013
doi: 10.1159/000509013
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

328-333

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Manuel Medina-Rodriguez (M)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.

Manuel Millan-Vazquez (M)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.

Elena Zapata-Arriaza (E)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Interventional Neuroradiology, Radiology Department, University Hospital Virgen del Rocío, Sevilla, Spain.

Irene Escudero (I)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Neurovascular Lab, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

Blanca Pardo-Galiana (B)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Neurovascular Lab, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

Juan Antonio Cabezas-Rodriguez (JA)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Neurovascular Lab, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

Lucia Lebrato-Hernandez (L)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Neurovascular Lab, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.

Joaquin Ortega-Quintanilla (J)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Interventional Neuroradiology, Radiology Department, University Hospital Virgen del Rocío, Sevilla, Spain.

Asier de Albóniga-Chindurza (A)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Interventional Neuroradiology, Radiology Department, University Hospital Virgen del Rocío, Sevilla, Spain.

Rafael Felix Ocete-Perez (RF)

Radiology Department, University Hospital Virgen del Rocío, Sevilla, Spain.

Juan Jurado-Serrano (J)

Radiology Department, University Hospital Virgen del Rocío, Sevilla, Spain.

Alejandro Gonzalez-Garcia (A)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain.
Interventional Neuroradiology, Radiology Department, University Hospital Virgen del Rocío, Sevilla, Spain.

Aurelio Cayuela (A)

Unit of Clinical Management of Public Health, Prevention and Promotion of Health, Area of Sanitary Management South of Sevilla, Sevilla, Spain.

Francisco Moniche (F)

Stroke Unit, University Hospital Virgen del Rocío, Sevilla, Spain, pmoniche@gmail.com.
Neurovascular Lab, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain, pmoniche@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH